Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > COMMENTARY
COMMENTARY
-
JPMA Update (12)
November 22, 2004
-
JPMA Pudate(11)
November 15, 2004
-
JPMA Update (10)
November 8, 2004
-
JPMA Update (9)
November 1, 2004
-
JPMA Update (8)
October 25, 2004
-
JPMA Update (7)
October 18, 2004
-
JPMA Update (6)
October 11, 2004
-
＜Special Contribution＞
October 4, 2004
-
JPMA Update (5)
October 4, 2004
-
JPMA Update(4)
September 27, 2004
-
JPMA Update (3)
September 20, 2004
-
JPMA Update (2)
September 13, 2004
-
＜New Series＞
September 6, 2004
-
June 7, 2004
-
May 24, 2004
-
BULLETIN
May 24, 2004
-
Brand Equity in the Pharmaceutical Industry
March 8, 2004
-
＜Special Contribution＞ Breakthrough Candidates from Japanese Pharmaceutical Industry in 2004 (2)
March 8, 2004
-
March 1, 2004
-
Pursuing the Value of the Japanese Pharm Industry (2)
February 9, 2004
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…